Abstract
As melanoma starts spreading to various parts of the body from where it started, it is known as advanced melanoma. This study compares the results of the mixture and non-mixture cure models with the standard parametric models while estimating the long-term survival probability of the patients treated with nivolumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
